Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...
Clinical trials continue to be a driving force in ophthalmology, propelling the development of innovative treatments and technologies that improve patient outcomes. Editor’s Note: This is part three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback